Delaware
Prescription drug spending and prescribing in Delaware, from Medicare Part D and Medicaid, with the life-science companies raising money there and state attorney general health-care antitrust cases. Compare every state.
In 2024, Medicare Part D plans paid $941M for prescriptions written in Delaware, the 45th most of 52 states and territories, and 3.7% of its claims were opioids against 3.5% nationally.
- Medicare Part D, 2024: $941M
- Medicaid drugs, 2025: $273M
- Opioid share of claims: 3.7%
- Life-science raises, 2 years: $130M
How It Prescribes
Medicare Part D, 2024, by the prescriber's state| Share of Part D claims | Delaware | United States | Difference |
|---|---|---|---|
| Opioids | 3.7% | 3.5% | +4% |
| Antibiotics | 4.4% | 4.4% | 0% |
| Antipsychotics | 1.7% | 1.7% | -4% |
Most Distinctive Drugs
Prescribed most out of line with the rest of the country: the drug's share of Delaware's claims against its share nationally| Drug | Against national rate | Claims |
|---|---|---|
| Oxycodone Myristate | 2.7× | 3,097 |
| Ezetimibe/Simvastatin | 2.6× | 2,165 |
| Bisoprolol Fumarate | 2.4× | 8,136 |
| Cefpodoxime Proxetil | 2.3× | 3,679 |
| Hydromorphone Hcl | 2.2× | 5,357 |
| Repaglinide | 2.1× | 2,359 |
| Morphine Sulfate | 1.9× | 15,207 |
| Oxycodone Hcl | 1.9× | 55,504 |
| Bisoprolol/Hydrochlorothiazide | 1.8× | 3,114 |
| Rsv Vacc, Pref A And Pref B/Pf | 1.7× | 8,595 |
Biggest Medicaid Drugs
What Delaware's Medicaid program paid pharmacies, before rebates; see every drugLife-Science Fundraising
54 Form D raises by companies based in Delaware in the last two years; the 10 largest. See all raises- Converge Bio Inc.$25M · Biotech · Apr 28, 2026
- HUMMINGBIRD HEALTHCARE, INC.$19M · Other health care · Mar 18, 2025
- TJM Labs, Inc.$10M · Other health care · Feb 18, 2026
- Halcyon Wellness Inc.$8M · Biotech · Mar 23, 2026
- Amalgam Rx, Inc.$8M · Other health care · Aug 15, 2025
- Ovelle Bio Corp.$7M · Biotech · Jun 10, 2026
- RxWare, Inc.$6M · Other health care · Aug 14, 2025
- SwitchPoint Bio Holding, Inc.$5M · Biotech · Mar 10, 2026
- My Diabetes Health, Inc.$4M · Other health care · Jun 13, 2025
- GPN VACCINES, INC.$4M · Biotech · Jan 28, 2026
State Attorney General Health-Care Cases
Antitrust cases Delaware joined, newest first; see every case- Connecticut, et al. v. Sandoz, et al., Case No. 20-cv-3539 (E.D. Pa. June 10, 2020), MDL 2724 (E.D. Pa.)2020 · Pending
- Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al., No. 2:19-cv-02407, (E.D. Pa. filed in MDL 05/30/2019)2019 · Pending
- California et al. v. Teikoku Seikayu Co.(Lidoderm), No. 3:18-cv-00675 (N.D. Cal. 01/31/18)2018 · Settled
- State of Wisconsin et al. v. Indivior, No. 16-5073 (E.D. Pa. Sept. 22,2016)2016 · Pending
- Connecticut et al. v. Teva Pharmaceuticals et al. Civ. Action No. (D.Conn. Dec. 15, 2016)2016 · Pending
- New York et al. v. Cephalon, No. 2:16-cv-04234 (E.D. Pa. Aug. 4, 2016)2016 · Settled
- Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)2006 · Settled
- State of Colorado et al v. Warner Chilcott, 1:05-cv-02182 (D.D.C.2005)2005 · Settled
- Maryland et al. v. Perrigo Company, No. 1:04CV01398 (D.D.C. Aug. 17, 2004)2004 · Settled
- Texas et al. v. Organon (Remeron), No. 04-5126 (D.N.J. 2004)2004 · Settled
Other States
Alabama · Alaska · Arizona · Arkansas · California · Colorado · Connecticut · District of Columbia · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kansas · Kentucky · Louisiana · Maine · Maryland · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · Montana · Nebraska · Nevada · New Hampshire · New Jersey · New Mexico · New York · North Carolina · North Dakota · Ohio · Oklahoma · Oregon · Pennsylvania · Puerto Rico · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · Utah · Vermont · Virginia · Washington · West Virginia · Wisconsin · Wyoming
Part D is by the prescriber's state, Medicaid by the paying state program, and Form D by the issuer's stated address. Amounts are before manufacturer rebates. Refreshed weekly. CMS Medicare Part D Prescribers by Geography; CMS State Drug Utilization Data; SEC Form D; NAAG